CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 51 enrolled
Drug / intervention
Zoledronic acid +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01267279
NCT01267279Phase 4Completed
CompareCT.gov

Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty

Spokane Joint Replacement Center·interventional·Posted Dec 28, 2010·Updated Dec 19, 2018

In Brief

A Phase 4 clinical trial evaluating Zoledronic acid and Placebo for Osteoporosis. Completed, enrolled 51 participants.

Detailed Summary

In a randomized, double-blind trial, BMD of the operated proximal femur after total hip replacement measured by dual-energy x-ray absorptiometry (DXA) were compared for up to two years in patients receiving IV ZOL 5 mg infusion (n = 27) or placebo (IV saline infusion; n = 24) at two weeks and one year after surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 28, 2010
Enrollment StartJan 1, 2005
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 9.9 yearsPosted 15.5 years ago

Interventions

Zoledronic aciddrug

Zoledronic acid per protocol

Placeboother

Placebo